Maruani, A;
(2018)
Bispecifics and antibody–drug conjugates: A positive synergy.
Drug Discovery Today: Technologies
, 30
pp. 55-61.
10.1016/j.ddtec.2018.09.003.
Preview |
Text
review_bispecifics_AM.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Bispecific antibodies (BsAbs) are antibodies with two different paratopes. In the past decade, advances in protein engineering have enabled the development of more than 100 formats of BsAbs. With two BsAbs approved for therapeutic use and more than 60 in clinical trials, this research area has shifted from being effervescent to being a mainstream therapeutic development topic. In parallel, recent progress in protein conjugation and cytotoxicity of small molecule drugs has resulted in a boom in monospecific antibody therapeutics development such as antibody–drug conjugates (ADCs). Recent examples have demonstrated how BsAbs approaches can be used to generate ADCs with better efficacy and safety profile. Rather than examining these two different yet similar areas independently, this minireview will explore the potential synergies that can exist between them.
| Type: | Article |
|---|---|
| Title: | Bispecifics and antibody–drug conjugates: A positive synergy |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ddtec.2018.09.003 |
| Publisher version: | https://doi.org/10.1016/j.ddtec.2018.09.003 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences > Dept of Chemistry |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10062130 |
Archive Staff Only
 |
View Item |
